MXPA06000917A - Modificaciones estables de maleato acido de tegaserod. - Google Patents

Modificaciones estables de maleato acido de tegaserod.

Info

Publication number
MXPA06000917A
MXPA06000917A MXPA06000917A MXPA06000917A MXPA06000917A MX PA06000917 A MXPA06000917 A MX PA06000917A MX PA06000917 A MXPA06000917 A MX PA06000917A MX PA06000917 A MXPA06000917 A MX PA06000917A MX PA06000917 A MXPA06000917 A MX PA06000917A
Authority
MX
Mexico
Prior art keywords
hydrogen maleate
tegaserod hydrogen
stable modifications
tegaserod
stable
Prior art date
Application number
MXPA06000917A
Other languages
English (en)
Inventor
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA06000917(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA06000917A publication Critical patent/MXPA06000917A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

La presente invencion se refiere a formas cristalinas del maleato acido de tegaserod; a su uso en composiciones farmaceuticas utiles en el tratamiento del sindrome de intestino irritable, de la enfermedad de reflujo gastroesofagico, de dispepsia funcional, de constipacion cronica o de diarrea, y a su produccion.
MXPA06000917A 2003-07-24 2004-07-23 Modificaciones estables de maleato acido de tegaserod. MXPA06000917A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24
PCT/EP2004/008281 WO2005014544A1 (en) 2003-07-24 2004-07-23 Stable modifications of tegaserod hydrogen maleate

Publications (1)

Publication Number Publication Date
MXPA06000917A true MXPA06000917A (es) 2006-03-30

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000917A MXPA06000917A (es) 2003-07-24 2004-07-23 Modificaciones estables de maleato acido de tegaserod.

Country Status (24)

Country Link
US (1) US20070112056A1 (es)
EP (2) EP1880992A1 (es)
JP (1) JP2006528609A (es)
KR (1) KR20060040710A (es)
CN (1) CN1826318A (es)
AR (1) AR045081A1 (es)
AU (1) AU2004263285A1 (es)
BR (1) BRPI0412830A (es)
CA (1) CA2532351A1 (es)
CO (1) CO5680418A2 (es)
EC (1) ECSP066306A (es)
IL (1) IL172914A0 (es)
IS (1) IS8321A (es)
MA (1) MA27935A1 (es)
MX (1) MXPA06000917A (es)
MY (1) MY137386A (es)
NO (1) NO20060915L (es)
NZ (1) NZ544596A (es)
PE (1) PE20050253A1 (es)
RU (1) RU2349585C2 (es)
SG (1) SG144944A1 (es)
TN (1) TNSN06024A1 (es)
TW (1) TW200510302A (es)
WO (1) WO2005014544A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045120A2 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
JP2008528615A (ja) * 2005-01-31 2008-07-31 ノバルティス アクチエンゲゼルシャフト プロトンポンプ阻害剤により誘発され得る遅延した胃内容排出の処置のための５−ｈｔ４アゴニストの使用
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070112057A1 (en) * 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate
WO2007119109A2 (en) * 2005-10-06 2007-10-25 Medichem, S.A. Processes for preparing tegaserod maleate and pharmaceutical compositions containing it
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (en) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Preparation of tegaserod maleate free of iodide
EP1956002A1 (en) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. New tegaserod maleate polymorphs and process for their preparation
AU2008252604A1 (en) * 2007-05-17 2008-11-27 Generics [Uk] Limited Process for the preparation of form A of tegaserod

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
RS50104B (sr) * 1998-08-21 2009-01-22 Novartis Ag., Nova oralna formulacija za 5-th4 agoniste ili antagoniste
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
US20070112057A1 (en) * 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate

Also Published As

Publication number Publication date
MA27935A1 (fr) 2006-06-01
IL172914A0 (en) 2006-06-11
PE20050253A1 (es) 2005-06-03
CO5680418A2 (es) 2006-09-29
AR045081A1 (es) 2005-10-12
TW200510302A (en) 2005-03-16
EP1651601A1 (en) 2006-05-03
TNSN06024A1 (en) 2007-10-03
IS8321A (is) 2006-02-22
AU2004263285A1 (en) 2005-02-17
ECSP066306A (es) 2006-07-28
CA2532351A1 (en) 2005-02-17
NO20060915L (no) 2006-04-24
US20070112056A1 (en) 2007-05-17
NZ544596A (en) 2009-01-31
RU2349585C2 (ru) 2009-03-20
MY137386A (en) 2009-01-30
KR20060040710A (ko) 2006-05-10
JP2006528609A (ja) 2006-12-21
EP1880992A1 (en) 2008-01-23
BRPI0412830A (pt) 2006-09-26
WO2005014544A1 (en) 2005-02-17
CN1826318A (zh) 2006-08-30
SG144944A1 (en) 2008-08-28
RU2006105481A (ru) 2007-09-20

Similar Documents

Publication Publication Date Title
TNSN06024A1 (en) Stable modifications of tegaserod hydrogen maleate
WO2002059107A8 (en) Substituted piperidines/piperazines as melanocortin receptor agonists
MY145810A (en) Il-8 receptor antagonists
PL1635824T3 (pl) 5-Członowe heterocykliczne inhibitory P-38
TW200509910A (en) Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
ATE302773T1 (de) Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
GEP20125565B (en) Lactam compounds and their pharmaceutical use
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE435206T1 (de) Heteroarylsulfonylstilbene als 5-ht2a- antagonisten
WO2006110406A3 (en) Compositions comprising probiotic and sweetener components
EA201070091A1 (ru) Производные пиперидина, пригодные в качестве антагонистов рецептора орексина
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
MX2009004771A (es) Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
WO2006072458A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2007124423A3 (en) Il-8 receptor antagonists
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
ATE442846T1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
TW200514781A (en) Novel compounds
EP1812112A4 (en) CHEMICAL COMPOUNDS
AP1548A (en) Il-8 Receptor Antagonists.
MXPA05003264A (es) Pirroles 3,4-disustituidos y su uso en el tratamiento de enfermedades inflamatorias.
MXPA05013537A (es) Derivados de indol.